Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus.
During normal pregnancy a dampening in T cell-mediated immunity is compensated by an increased pro-inflammatory activity. Likewise, the autoimmune disease systemic lupus erythematosus (SLE) is associated with inflammatory activity and pregnancy complications occur frequently in women with SLE. The aim of this study was to elucidate how SLE influences the chemokine and cytokine balance during and after pregnancy. Blood samples were taken from pregnant women with or without SLE at second and third trimester and 8-12 weeks after pregnancy. Cytokines (interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17A, TNF, IFN-γ and IFN-α), chemokines (CXCL8/IL-8, CXCL9/MIG, CXCL10/IP-10, CCL2/MCP-1, CCL5/RANTES and CCL17/TARC), soluble IL-6 receptor (sIL-6R) and soluble glycoprotein 130 (gp130) were measured in serum using cytometric bead array (CBA) or enzyme-linked immunosorbent assay (ELISA). Women with SLE had increased serum concentrations of CXCL8/IL-8, CXCL9/MIG, CXCL10/IP-10 and IL-10 compared to controls both during and after pregnancy. Further, when dividing the patients based on disease activity, the women with active disease had the highest levels. Importantly, women with SLE seemed to respond to pregnancy in a similar way as controls, since the changes of cytokines and chemokines over the course of pregnancy were similar but with overall higher levels in the patient group. In conclusion, changes in pro- and anti-inflammatory serum components during pregnancy in women with SLE, occurring on top of already more pro-inflammatory levels, might increase their risk for pregnancy complications and flares. How their children are affected by this heightened inflammatory milieu during pregnancy needs further investigation.
Department of Immunology, The Wenner-Gren Institute, Arrhenius Laboratories for Natural Sciences, Stockholm University, Stockholm, Sweden.
S
S
Björkander
K
K
Bremme
J-O
JO
Persson
R F
RF
van Vollenhoven
E
E
Sverremark-Ekström
U
U
Holmlund
D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D018925:Chemokines / Q000097:blood; D003710:Demography; D005260:Female; D006262:Health; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007371:Interferon-gamma / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D011247:Pregnancy; D037841:Pregnant People; D018123:Receptors, Interleukin / Q000097:blood; D019947:Receptors, Interleukin-6 / Q000097:blood; D015398:Signal Transduction
D015415:Biomarkers; D018925:Chemokines; C502188:IL31RA protein, human; D018836:Inflammation Mediators; D018123:Receptors, Interleukin; D019947:Receptors, Interleukin-6; D007371:Interferon-gamma